UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development today.
Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases. Mecillinam, an intravenous (IV) formulation, is being developed as a first-line therapy for complicated UTI (cUTI) in the hospital setting.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 1 Ashley Road, Altrincham,england Wa14 2dt,united Kingdom
- Phone
- +44 203 930 9665
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- utilitytherapeutics.com
- HQ
- Altrincham, England
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.) Questions
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.)'s helpline number is +44 203 930 9665
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.)'s website is utilitytherapeutics.com
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.)'s LinkedIn profile is https://uk.linkedin.com/company/utilitytherapeutics
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.) has
4 employees.
View email and phone details for 4
employees at Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.).
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.)'s industry is
Biotechnology Research
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.)'s top competitors are
Alembic Pharmaceuticals Limited,
Antabio,
Elion Therapeutics,
Pattern Bioscience,
Biomx (Nyse: Phge),
Biomedical Advanced Research And Development Authority (Barda),
Vedanta Biosciences, Inc.,
Venatorx Pharmaceuticals, Inc.,
Bioversys Ag,
Union Therapeutics A/s.
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.)'s support email address is info@utilitytherapeutics.com
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.)'s categories are Biotechnology Research
Utility Therapeutics (Acquired By Alembic Pharmaceuticals Inc.)'s founding year is 2017
